APO-CEPHALEX 250 MG
CEPHALEXIN (CEPHALEXIN MONOHYDRATE) : 250 MG · DIN 00768723 · APOTEX INC
Health Canada status: MARKETED
What is APO-CEPHALEX?
APO-CEPHALEX 250 MG contains CEPHALEXIN (CEPHALEXIN MONOHYDRATE) : 250 MG. It is listed in the Health Canada Drug Product Database under DIN 00768723, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 31-Dec-1988. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-CEPHALEX used for?
Treatment of bacterial infections of the respiratory tract (including otitis media), genitourinary tract, bones and joints, and skin and soft tissue caused by susceptible organisms.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 00768723 |
|---|---|
| Brand name | APO-CEPHALEX |
| Generic / active ingredient | CEPHALEXIN (CEPHALEXIN MONOHYDRATE) : 250 MG |
| Manufacturer | APOTEX INC |
| Strength | 250 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | J01DB01 CEFALEXIN |
| AHFS class | 08:12.06.04 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 31-Dec-1988 |
| Original market date | 1988-12-31 00:00:00 |
How is it administered?
Adults: 1-4 g daily in divided doses (usually 1 g/day every 6 hours). Children: 25-50 mg/kg/day in divided doses every 6 hours. Administer on an empty stomach for maximum peak levels.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at room temperature (15°C to 30°C) in a tightly closed, light-resistant container.
How is it supplied?
250 mg: Bottles of 100 and 1000 tablets. 500 mg: Bottles of 100 and 500 tablets.
Contraindications
Known allergy to the cephalosporin group of antibiotics.
Warnings and precautions
Hypersensitivity (cross-allergenicity with penicillins); Severe Cutaneous Adverse Reactions (SCAR); Clostridium difficile-associated disease (CDAD); risk of drug-resistant bacteria development.
What can be used instead?
Other Canadian products sharing ATC code J01DB01 CEFALEXIN. 23 of 47 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-CEPHALEX | 500 MG | TABLET | APOTEX INC | MARKETED | DIN 00768715 |
| AURO-CEPHALEXIN | 125 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02497743 |
| AURO-CEPHALEXIN | 250 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02470578 |
| AURO-CEPHALEXIN | 250 MG / 5 ML | POWDER FOR SUSPENSION | AURO PHARMA INC | MARKETED | DIN 02497751 |
| AURO-CEPHALEXIN | 500 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02470586 |
| CEPHALEXIN | 250 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02521253 |
| CEPHALEXIN | 500 MG | TABLET | SIVEM PHARMACEUTICALS ULC | MARKETED | DIN 02495651 |
| CEPHALEXIN | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02521261 |
| JAMP CEPHALEXIN | 250 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02494698 |
| JAMP CEPHALEXIN | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02494701 |
Who else supplies CEFALEXIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CEFALEXIN appears in 447 registered pack listings across 9 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.